The Keller Laboratory at cc-TDI

Monday, May 5, 2008

Welcoming Michelle Brady!

We would like to Welcome Michelle Brady to the GCCRI as the new Technical Director of the GCCRI Mouse Histology Facility. This resource facility, managed jointly by Michelle and Charles, provides specialized pathology resources for preclinical mouse models of childhood cancers. Michelle brings to this enterprise over 23 years professional experience in Histology and Immunohistochemistry. We are so lucky to have Michelle on our team!

Wednesday, April 23, 2008

Nobel Laureate Mario Capecchi, Ph.D., visits HSC

Charles' mentor visits our university.

Staff writer, "Nobel Laureate Mario Capecchi, Ph.D., visits HSC", HSC News (UTHSCSA), April 23, 2008 [interview]

Friday, February 15, 2008

Special Report: Open Laboratories

The Greehey Children's Cancer Research Institute is an example of a new movement in architecture and scientific culture.

San Antonio Business Journal, Special Report: Open Laboratories (interview). February 15, 2008, 21(54):28,33

Saturday, December 1, 2007

Top 40 under Forty

Charles is recognized as one of San Antonio's Rising Stars. But as GCCRI Director, Dr Sharon Murphy reminds us, "to those who have been given much, much is expected".

San Antonio Business Journal, Top 40 under Forty. Decemeber 2007, 21(47):23B

Saturday, October 13, 2007

ChiliFest 2007

Kelly and Charles were proud to host our 3rd Annual ChiliFest competition. It's a relaxing way to get together outside of the lab, and to test the hypothesis that the most talented laboratory scientists make the best cooks!

Monday, May 21, 2007

Megan E. Gentry (Summer Intern, 5/21/07 - present)

Megan recieved an UTHSCSA medical student research project stipend (1st Prize Poster, 2007 Student Research Day, 9/18/07).

Friday, December 1, 2006

Personalized Medicine

A discussion about personalized medicine with State Science Advisor Greg Jones; Michael Paul of Utah-based Lineagen Partners; Dr. Charles Keller, principal investigator, Children's Cancer Research Institute in San Antonio; and Elliot Parks of Hamilton BioVentures. Click here to listen.

Radio Interview, National Public Radio (NPR - KCPW, Salt Lake City). "Personalized Medicine". Panel discussion with Lara Jones as moderator.

You Can Participate in our Novel Therapeutics Studies !

One would like to think that tangibly better treatments for rhabdomyosarcoma, medulloblastoma and other childhood cancers can be found in a matter of years, instead of tens of years. Finding new treatments starts with research, perhaps even a new research approach to identifying effective new treatments. The Children's Cancer Therapy Development Institute focuses on finding molecules in childhood cancers that can be directly turned off or on by drugs so that the tumor stops growing. Behind our novel approach is the use of genetically-engineered mice. Our Pediatric Preclinical Testing Initiative uses mice modified from before birth so that at a certain age, and in a certain tissue, the same mutations found in a child’s cancer are activated in the mouse. These special mouse models of childhood cancer can be used to test a treatment to see whether the tumor growth and spread (metastasis) can be reversed. The specific aspect of these mice having normal immune systems is a real plus, too, because white blood cells play an important role in how tumors evolve and respond to therapy.

Our program is designed around community participation. Through the Children's Cancer Therapy Development Institute, you can contribute directly to this grass-roots initiative. Donations through small gifts or grants will assist in studying compounds that may be effective in treating such childhood cancers as alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, or medulloblastoma (the alveolar rhabdomyosarcoma model was featured by Dr. Keller's long time collaborator and former mentor, 2007 Nobel laureate Mario Capecchi, in his Nobel Prize lecture {see 16 minutes onward}.)

For additional information regarding supporting this program please contact Charles Keller at charles@cc-tdi.org. Results obtained through these studies will be shared with the National Cancer Institute’s Cancer Therapy Evaluation Program, as well as the Children’s Oncology Group, which designs clinical trials for childhood cancer.